Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

Leukemia

Volumn 29, Issue 2, 2015, Pages 377-386

  Kohnke T ^a   Sauter, D ^a   Ringel, K ^a   Hoster, E ^a   Laubender, R P ^a   Hubmann, M ^a   Bohlander, S K ^a,b   Kakadia, P M ^b   Schneider, S ^a   Dufour, A ^a   Sauerland, M C ^c   Berdel, W E ^c   Buchner T ^c   Wormann B ^d   Braess, J ^e   Hiddemann, W ^a,f   Spiekermann, K ^a,f,g   Subklewe, M ^a,f  

^a UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d German Society of Hematology and Oncology   (Germany)

^e Barmherzige Brüder Hospital   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; NUCLEOPHOSMIN; TIOGUANINE; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APLASIA; ARTICLE; BONE MARROW APLASIA; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK POPULATION; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MORPHOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE FREE SURVIVAL; RISK FACTOR; AGED; BLOOD; BONE MARROW; BONE MARROW CELL; CONGENITAL MALFORMATION; CYTOLOGY; DISEASE FREE SURVIVAL; GENETICS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; BONE MARROW; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84927171034     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.186     Document Type: Article

References (37)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
2. Roöllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29: 2758-2765.
3. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) Acute Myeloid Leukemia [Internet]. nccn.org. 2012 [cited 30 September 2013]. Available from: http://www.nccn.org/professionals/physician-gls/pdf/aml.pdf.
5. Ofran Y, Rowe JM. Induction and postremission strategies in acute myeloid leukemia: what is new? Curr Opin Hematol 2011; 18: 83-88.
6. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116: 3147-3156.
7. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Coco Lo F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341.
8. Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116: 2295-2303.
9. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2008; 131: 16-26.
10. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acutemyeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552.
11. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29: 2709-2716.
12. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123-4131.
13. San Miguel JF, Martínez A, Macedo A, VidrialesMB, López-Berges C, González M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
14. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96 : 3948-3952.
15. Kern W. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-3085.
16. Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A Study. J Clin Oncol 2013; 31: 3889-3897.
17. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
18. Bertoli S, Bories P, Bene MC, Daliphard S, Lioure B, Pigneux A et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica 2013; 99: 46-53.
19. Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012; 30: 3625-3632.
20. Braess J, Spiekermann K, Staib P, Gruneisen A, Wörmann B, Ludwig WD et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113: 3903-3910.
21. Buchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116-4124.
22. Buchner T. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480-2489.
23. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
24. Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol 2008; 143: 230-239.
25. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28: 570-577.
26. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-2231.
27. Grimwade D, Hills RK, Moorman AV, Walker H, Goldstone AH, Chatters S et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
28. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb H-J et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of 385 leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003; 88: 646-653.
29. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
30. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120: 1581-1588.
31. Sievers EL. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398-3406.
32. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012; 2012: 35-42.
33. Paietta E. When it comes to MRD, AMLaALL. Blood 2012; 120: 1536-1537.
34. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468-472.
35. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
36. Schrappe M. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program 2012; 2012: 137-142.
37. Terwijn M, Kelder A, Snel AN, Rutten AP, Scholten WJ, Oussoren YJM et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol 2012; 34: 432-441.